Ectopic Calcification and Hypophosphatemic Rickets: Natural History of ENPP1 and ABCC6 Deficiencies

Carlos R Ferreira,1 Kristina Kintzinger,2 Mary E Hackbarth,1 Ulrike Botschen,2 Yvonne Nitschke,2 M Zulf Mughal,3 Genevieve Baujat,4 Dirk Schnabel,5 Eric Yuen,6 William A Gahl,1 Rachel I Gafni,7 Qing Liu,8 Carlos R Ferreira,1

1Department of General Pediatrics, Münster University Children’s Hospital, Münster, Germany
2Department of Paediatric Endocrinology, Royal Manchester Children’s Hospital, Manchester, UK
3Centre de Référence Maladies Ostéoporiques (CROS) et Maladies du Phosphore (CR MOC) et Filière OSCAR, Département de Genétique, Hôpital Necker-Enfants Malades, Paris, France
4Department of Paediatric Endocrinology, Royal Manchester Children’s Hospital, Manchester, UK
5Department of Paediatric Endocrinology, Charité-Universitätsmedizin Berlin, Berlin, Germany
6Inozyme Pharma, Inc., Boston, MA, USA
7National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
8Quantitative & Regulatory Medical Science, LLC, Long Valley, NJ, USA

ABSTRACT
Generalized arterial calcification of infancy (GACI) is a rare disorder caused by ENPP1 or ABCC6 variants. GACI is characterized by low pyrophosphate, arterial calcification, and high mortality during the first year of life, but the natural course and possible differences between the causative genes remain unknown. In all, 247 individual records for patients with GACI (from birth to 58.3 years of age) across 19 countries were reviewed. Overall mortality was 54.7% (13.4% in utero or stillborn), with a 50.4% probability of death before the age of 6 months (critical period). Contrary to previous publications, we found that bisphosphonate treatment had no survival benefit based on a start-time matched analysis and inconclusive results when initiated within 2 weeks of birth. Despite a similar prevalence of GACI phenotypes between ENPP1 and ABCC6 deficiencies, including arterial calcification (77.2% and 89.5%, respectively), organ calcification (65.8% and 84.2%, respectively), and cardiovascular complications (58.4% and 78.9%, respectively), mortality was higher for ENPP1 versus ABCC6 variants (40.5% versus 10.5%, respectively; p = 0.0157). Higher prevalence of rickets was reported in 70.8% of surviving affected individuals with ENPP1 compared with that of ABCC6 (11.8%; p = 0.0001). Eleven affected individuals presenting with rickets and without a GACI diagnosis, termed autosomal recessive hypophosphatemic rickets type 2 (ARHR2), all had confirmed ENPP1 variants. Approximately 70% of these patients demonstrated evidence of ectopic calcification or complications similar to those seen in individuals with GACI, which shows that ARHR2 is not a distinct condition from GACI but represents part of the spectrum of ENPP1 deficiency. Overall, this study identified an early mortality risk in GACI patients despite attempts to treat with bisphosphonates, high prevalence of rickets almost exclusive to ENPP1 deficiency, and a spectrum of heterogeneous calcification and multiple organ complications with both ENPP1 and ABCC6 variants, which suggests an overlapping pathology. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). This article has been contributed to by US Government employees and their work is in the public domain in the USA.

KEY WORDS: ABCC6 deficiency; diseases and disorders of related to bone; ectopic calcification; ectopic calcification; ENPP1 deficiency; Generalized Arterial Calcification of Infancy; hypophosphatemic rickets; natural history study; osteomalacia; rickets; survival analysis

Introduction
Generalized arterial calcification of infancy (GACI) is a rare autosomal recessive disorder characterized by calcification of arteries and marked neointimal proliferation leading to arterial stenoses and cardiac complications.1) Individuals with GACI also develop calcification in joints and parenchymal organs and demonstrate renal, gastrointestinal, and pulmonary complications.2,3)
The disease can manifest prenatally and has a mortality of ~55% in the first 6 months of life despite intensive therapy (critical mortality period). However, the disease course after the initial 6 months is not well characterized, with reports limited to case series or small retrospective studies.

Biallelic inactivating variants in ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) or ABCG6 (ATP binding cassette subfamily C member 6) account for ~75% and 9% of GACI cases, respectively. ENPP1 is an integral transmembrane protein that hydrolyzes extracellular adenosine triphosphate (ATP) to inorganic pyrophosphate (PP) and adenosine monophosphate (AMP). PP is a potent inhibitor of calcium hydroxyapatite crystal deposition and is essential to prevent ectopic soft tissue calcification. AMP is further hydrolyzed to adenosine, a potent inhibitor of neointimal proliferation. Vascular calcification and arterial stenosis are thought to occur as a result of the reduction in PP, and AMP, respectively. Enpp1 knockout mice show a similar phenotype to patients diagnosed with GACI: low serum PP, extensive arterial calcification, arterial stenosis, and calcification of selected organs. Although the exact role of ABCG6 in GACI is not well understood, reduction in serum PP, levels and ectopic calcifications are also observed in mouse models and patients with ABCG6 variants, which suggests a common PP pathway between ENPP1 and ABCG6 deficiencies. However, it is not clear if the clinical profile and disease course are similar between ABCG6 and ENPP1 variants.

Individuals with GACI who survive infancy have been reported to progress to autosomal recessive hypophosphatemic rickets type 2 (ARHR2). ARHR2 manifests clinically as short stature and bone deformities and is associated with ENPP1 variants, but it has not been reported to be associated with ABCG6 variants. GACI survivors have been found to have elevated fibroblast growth factor 23 (FGF23), and this may contribute to the hypophosphatemic rickets and osteomalacia.

A genotypic and phenotypic overlap of GACI with pseudoxanthoma elasticum (PXE) has been reported. Classic PXE is caused by ABCG6 variants, manifests as soon as the second decade of life with skin changes, and is characterized by mineralization and fragmentation of elastic fibers in skin, eyes, and cardiovascular system. There are case reports of individuals diagnosed with GACI due to ENPP1 variants who developed PXE-like symptoms, which suggests that PXE-like symptoms may not be limited to genotype but to a common mechanism of low PP, and ectopic calcification.

The natural history of GACI, in particular its mortality, relation to rickets, and phenotypic differences based on genetic loci, has not been comprehensively elucidated, limiting effective diagnosis, prognosis, and management. This study describes the natural history of GACI, role of bisphosphonates in survival, and phenotypic similarities/differences between ENPP1 and ABCG6 deficiencies.

Patients and Methods

Study design and patients

This retrospective international cross-sectional study included individuals with GACI or ARHR2 confirmed by imaging, biopsy, biochemical findings, and/or ENPP1 or ABCG6 variants or by parental mutational analysis indicating ENPP1/ABCG6 variants consistent with symptoms of affected individuals. No exclusion criteria were implemented. Data were compiled from two primary studies by the US National Institutes of Health (NIH) (NCT03478839) and Germany’s Münster University Children’s Hospital (UKM) (NCT03758534). Data from cases diagnosed between 1960 and 2018 (median, 2010) were retrieved between 2018 and 2020. The study was conducted in accordance with the Declaration of Helsinki and with approval from local institutional review board/ethics commissions prior to data collection. Data from living affected individuals or legal guardians of minors were collected after obtaining consent. For deceased affected individuals, data were collected from legal guardians or physicians.

Procedures

Data were extracted retrospectively from medical chart reviews to develop case report forms (CRFs); CRFs for the two primary study sites were almost identical, allowing data combination. The CRFs included details on vital status, diagnosis, mutational analysis, medical/birth histories, initial postnatal GACI presentation, clinical course, treatments, and laboratory results—the full data set. When data were available but no consent was obtained from affected individuals/legal guardians (eg, deceased individuals), or when physicians were unwilling to participate, a five-item questionnaire was used. Information on vital status (if alive, current age; if deceased, age at death), history of bisphosphonates, and rickets or PXE diagnosis was collected for the minimal data set. A greater nonparticipation rate among physicians of deceased affected individuals was anticipated; this could result in biased overestimate of survival. Thus, the minimal data set was included to mitigate this bias and to obtain accurate survival estimate.

Data collection and management

The identity of affected individuals remained confidential during data transfer. In the NIH study, medical records were collected and reviewed by site staff, and extracted data were entered directly into an electronic data capture system, exported, and transferred securely. Source data verification of key information was conducted. In the UKM study, the treating physician extracted the data from medical charts and entered the data directly into an electronic CRF (eCRF). Any inconsistent data were clarified via physician consultation; duplicate data sets were removed. Data were combined using R 9.4 (R Foundation for Statistical Computing, Vienna, Austria; https://www.r-project.org/).

Outcomes

The primary objective was to characterize survival. Secondary objectives were to characterize natural history of GACI, elucidate role of bisphosphonates in survival, and assess clinical differences between ENPP1 and ABCG6 deficiencies.

Statistical analysis

Descriptive statistics were calculated to summarize data. Survival rates were determined using Kaplan-Meier analysis. Age at death or age last known alive was used for survival calculation; where only month and year of birth and death were available, the day was imputed to the first of the month for birth and last of the month for death. For individuals who died in utero or were stillborn, the age at death was set to 0. In the minimal data set, two affected individuals were excluded because age at death was not
specified \((n = 1)\) and age at last follow-up was unavailable \((n = 1)\); age at death or last known alive was imputed for nine affected individuals. In the full data set, dates of birth \((n = 69)\) and death \((n = 8)\), and ages of affected individuals who died in utero or were stillborn \((n = 10)\), were imputed as described. An affected individual start-time matched analysis was used to assess the outcome of bisphosphonate treatment on survival. Statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA) and RStudio 1.2.1335 (RStudio; https://www.rstudio.com/).

**Results**

The data set \((N = 247)\) included 127 affected individuals in the full data set \((56\) from NIH and \(71\) from UKM) and 120 affected individuals in the minimal data set \(\) (eight from NIH and \(112\) from UKM). The data from the five-item questionnaire for the minimal data set are included in Table 1.

**Demographics**

Of the affected individuals in the full data set \((n = 127)\), 52.8% were male, 46.5% were female, and sex was unknown in one individual. Consanguinity of biological parents was documented in 27 cases \((21.3\%)\) and unknown in 37 \((29.1\%)\). Diagnoses of individual. Consanguinity of biological parents was documented were male, 46.5% were female, and sex was unknown in one

| Parameter                        | All affected individuals \((N = 247)\) | Minimal data set \((n = 120)\) | Full data set \((n = 127)\) | ENPP1 data set \((n = 84)\) | ABCG6 data set \((n = 19)\) |
|----------------------------------|--------------------------------------|--------------------------------|----------------------------|----------------------------|----------------------------|
| Follow-up age (months), mean     | 53.2 (0.0–709.7)                     | 28.7 (0.0–420.3)               | 27.4 (0.0–709.7)           | 34.4 (0.0–709.7)           | 83.2 (0.1–154.4)           |
| (range)                          |                                      |                                |                            |                            |                            |
| Gender, female/male              |                                      | 59/67 (46.8)                   | 41/42 (49.4)               | 7/12 (36.8)                |
| (% female)                       |                                      |                                |                            |                            |                            |
| GACI                             |                                      |                                | 115/11 (91.3)              | 73/11 (86.9)               | 18/0 (100)                 |
| Yes/no (% yes of assessed)       |                                      |                                | 0.8 (–4.7 to 137.0)       | 0.7 (–4.7 to 137.0)       | 3.0 (–3.1 to 73.4)         |
| Age at diagnosis (months), median range\(^a\) | | 40/69 (36.7) | 36/38 (48.6) | 3/18 (16.7) |
| Rickets                          |                                      |                                | 52.9 (0.5–222.1)          | 27.5 (8.2–46.7)           |
| Yes/no (% yes of assessed)       |                                      | 52.9 (0.5–348.0)              | 204 (48.0–348.0)          | 38.3 (0.5–222.1)          |
| Age at diagnosis (months), median range\(^b\) | | | 137.0 | 137.0 | 137.0 |
| PXE                              |                                      | 45/164 (27.4)                 | 5/95 (5.0)                | 36/38 (48.6)              |
| Yes/no (% yes of assessed)       |                                      | 49.7 (2.7–542.0)              | 8.0 (8.0–8.0)             | 56/3 (7.4)                |
| Age at diagnosis (months), median range\(^b\) | | | 72.7 (2.7–524.0) | 115.0 (26.6–524.0) | 4.5 (2.7–6.2) |
| Bisphosphonate treatment         |                                      | 9/197 (4.4)                   | 1/99 (1.0)                | 56/3 (7.4)                |
| Yes/no (% yes of assessed)       |                                      | 49.7 (2.7–524.0)              | 8.0 (8.0–8.0)             | 56/3 (7.4)                |
| Alive, n (%)                     |                                      | 49.7 (2.7–524.0)              | 8.0 (8.0–8.0)             | 56/3 (7.4)                |
| Last known age (months), median range\(^b\) | | | 72.7 (2.7–524.0) | 115.0 (26.6–524.0) | 4.5 (2.7–6.2) |
| Deceased, n (%)                  |                                      | 135 (54.7)                    | 75 (63.5)                 | 59 (46.5)                 |
| Age at death (months), median range\(^b,c\) | | | 0.8 (0.0–182.5) | 1.2 (0.0–127.0) | 3.9 (0.1–7.7) |
| Prenatal death (%)               |                                      | 13.30                         | 19.20                     | 7.90                      |
| Deceased in utero, n             |                                      | 21                            | 14                        | 7                         |
| Stillborn, n                     |                                      | 12                            | 9                         | 3                         |

\(^a\)Isolated variant: does not include 3 affected individuals (all 3 deceased) with both ENPP1 and ABCG6 variants.

\(^b\)Based on available dates.

\(^c\)For those who were stillborn or died in utero, the age at death was set to 0 months.

**Mortality**

The overall mortality of all affected individuals \((N = 247)\) was 54.7\%, of which 33 died in utero or were stillborn, accounting for 24.4\% of total deaths \((Table 1)\). Mortality was higher in the minimal data set \((63.5\%)\) compared with that in the full data set \((46.5\%)\), and median age at death was lower in the minimal data set \(0.2\) months compared with that in the full data set \(1.2\) months. Of the affected individuals in the full data set with
a recorded cause of death (n = 52), cardiovascular complications (cardiac arrest, heart failure, myocardial infarction) were most prevalent (32.7%).

Kaplan-Meier survival estimates demonstrated high risk of mortality within the first 6 months of life and became stable with increasing age (Fig. 2A,B). The probability of mortality at 6 months was 50.6% for the total population (38.8% and 64.1% in full and minimal data sets, respectively). In the full data set, 55.2% (63/114 assessed) were treated with bisphosphonates (Table 2). A breakdown of the top three used bisphosphonates is presented in Table 2 including patients that used multiple agents. There were a number of missing doses, wide range of doses and inconsistent delivery, or frequency not reported. Initiation of bisphosphonate varied during the critical period of the first 6 months (Fig. 3A). Delay in initiating bisphosphonate after the first few weeks or months when mortality risk is lower than at birth might offer affected individuals a survival bias with respect to bisphosphonate treatment. In order to assess if treatment with bisphosphonate would offer a survival advantage, we focused on the first 6 months of age where the risk of mortality is highest. An affected individual start-time matched estimate was used to compare the risk of mortality in affected individuals. In short, each affected individual who initiated bisphosphonate prior to 6 months of age was matched by age to affected individuals not receiving bisphosphonate, and risk of mortality from that age forward was compared. Because of the small number of etidronate-treated affected individuals for a matched analysis, all bisphosphonate classes were included. There was no statistically significant survival benefit between individuals treated with bisphosphonate and those untreated (Fig. 3B). The confidence intervals overlapped after the first month of life, which suggests inconclusive benefit of early treatment within 1 month of age. Additionally, a Kaplan-Meier survival analysis was performed focused on affected individuals who initiated etidronate within 6 months of age, other bisphosphonates (no etidronate) initiated within 6 months of age, and affected individuals who did not receive bisphosphonates. The analysis demonstrated significant survival benefit for either etidronate or other bisphosphonates versus untreated at 1 year (74%, 74% versus 47%, respectively; log-rank [Cox-Mantel] test p = 0.0025 and p = 0.0175) (Fig. 3C); however, there was no statistical difference in survival if etidronate or any other bisphosphonate was

![Fig 1. Overlap of GACI, rickets, and PXE diagnoses in affected individuals in the full data set (n = 126). One individual manifested only widespread arterial stenoses, but not calcification, rickets, or PXE-like changes, and thus was not included. ARHR2 = autosomal recessive hypophosphatemic rickets type 2; GACI = generalized arterial calcification of infancy; PXE = pseudoxanthoma elasticum.]

![Fig 2. Survival analysis. Kaplan-Meier estimates of survival in all, full, and minimal data sets at (A) 0–30 years and (B) 0–1 year. Number of affected individuals at risk

|               | All affected individuals | Full data set | Minimal data set |
|---------------|--------------------------|---------------|-----------------|
| All affected  | 244                      | 127           | 117             |
| Full data set | 63                       | 50            | 13              |
| Minimal data  | 39                       | 29            | 10              |
|               | 25                       | 19            | 5               |
|               | 14                       | 9             | 5               |
|               | 11                       | 6             | 5               |
|               | 3                        |               |                 |

Journal of Bone and Mineral Research
Table 2. Bisphosphonate Use in the Full Data Set

| Parameter               | Use of bisphosphonate, yes/assessed (% yes) | Age at initiation, median month (range) |
|-------------------------|---------------------------------------------|----------------------------------------|
| Full data set (n = 127) |                                             |                                        |
| All bisphosphonates     | 63/114 (55.2)                               |                                        |
| Etidronate              | 42/63 (66.7)                                | 1.6 (−3.1 to 342)                      |
| Pamidronate             | 29/63 (46)                                  | 0.8 (0.0–70.7)                         |
| Risedronate             | 9/63 (14.2)                                 | 2.6 (0.6–66.7)                         |
| Multiple agents         | 40/63 (63.5)                                |                                        |
| ENPP1 (n = 84)          |                                             |                                        |
| All bisphosphonates     | 45/75 (60.0)                                |                                        |
| Etidronate              | 27/45 (60.0)                                | 1.2 (−3.1 to 342.0)                    |
| Pamidronate             | 22/45 (48.9)                                | 0.7 (0.0–70.7)                         |
| Risedronate             | 8/45 (17.8)                                 | 2.0 (0.6–66.7)                         |
| Multiple agents         | 29/45 (64.4)                                |                                        |
| ABCC6 (n = 19)          |                                             |                                        |
| All bisphosphonates     | 13/19 (68.4)                                |                                        |
| Etidronate              | 13/13 (100.0)                               | 5.5 (−1.6 to 62.5)                     |
| Pamidronate             | 5/13 (38.5)                                 | 2.0 (0.7–3.4)                          |
| Risedronate             | 0/13 (0.0)                                  |                                        |
| Multiple agents         | 9/13 (69.2)                                 |                                        |

initiated 7 days or later after birth (p = 0.1233, p = 0.4157, respectively) (Fig. 3D).

Phenotype in ENPP1 versus ABCC6 deficiencies

The risk of mortality by 6 months and 12 months was significantly higher in affected individuals with ENPP1 (n = 84; 33.5%, 37%, respectively) versus ABCC6 variants (n = 19; 5.3%, 10.8%, respectively) (log-rank [Cox-Mantel] test \( p = 0.0214 \) (Fig. 4A,B). The 21 affected individuals with no identified sequence variants in ENPP1 or ABCC6 had a higher mortality rate (probability of mortality at 6 months: 95%) than the other two cohorts. Of the 21 affected individuals, mutational analysis was performed on seven affected individuals but no variants were reported. Six affected individuals had mother and father with identified ENPP1 variants, but no affected individuals had parents with identified ABCC6 variants. When the six affected individuals with parents carrying an ENPP1 variant are included in the ENPP1 cohort, the 6-month and 12-month risk of mortality was 36.8% and 41.3%, respectively.

Prevalence of calcification of aorta, other arteries, organs, and joints in ENPP1 and ABCC6 deficiencies are shown in Fig. 5; these were calculated based on those affected individuals who were assessed (%Yes/Yes + No) at specific locations. The prevalence of calcification of individual arteries or organs ranged from 25% to 89% of patients with ENPP1 or ABCC6 variants. Overall, the prevalence of calcification was very similar, and location of calcification was not significantly different between ENPP1 and ABCC6 deficiencies, with the exception of joint calcification, which was reported in a significantly higher percentage of patients with ENPP1 deficiency. Methods of imaging assessment of calcification are shown in Supplemental Table S1. There is no significant difference in the frequency of organ complications between ENPP1 and ABCC6 deficiencies, ranging from 35% to 79% (Fig. 5A). Prevalence of hearing complications was higher in affected individuals with ENPP1 variants (28/56 [50.0%]) versus ABCC6 variants (0/14 [0.0%]; \( p = 0.0004 \)) (Fig. 5A). Approximately 50% of patients experienced complications in at least three organ systems (cardiac, pulmonary, gastrointestinal, neurological, or hearing) (Fig. 5B); there was no difference between the ENPP1 and ABCC6 cohorts. The most frequently reported signs/symptoms, location of calcification, and organ complications are provided in Supplemental Figs. S1 and S2.

Clinical signs of rickets were reported in 40 of 127 affected individuals (36.7%) in the full data set (Table 1); this prevalence was higher in affected individuals with ENPP1 variants (36/38 [48.6%]) than in those with ABCC6 variants (3/18 [16.7%]). Figure 5C shows the most frequently reported rickets-related manifestations. Of the 50 surviving affected individuals with ENPP1 variants, 34 of 48 assessed (70.1%) developed rickets. Eleven affected individuals were diagnosed with rickets or osteomalacia without a prior GACI or PXE diagnosis, a category designated as ARHR2 (Fig. 1); all had confirmed ENPP1 variants and median age (range) at diagnosis was 5.4 (2.2–54.5) years. Further assessments revealed seven of 11 (64%) affected individuals had evidence of calcification (three of nine assessed had arterial calcification; three of nine had cardiac valve calcification; two of three had periarticular calcification) and eight of 11 (72%) had organ complications (one of eight had cardiac failure; four of nine had heart valve defect; and four of nine had hearing complications) (data not shown).

Discussion

This retrospective study is the largest to date of individuals with GACI with or without ARHR2 (\( N = 247 \)), reporting the complications of GACI and hypophosphatemic rickets over a broad age range.\(^{4,7} \) The study found that the clinical spectrum for ENPP1 and ABCC6 deficiencies ranges from high risk of death before 6 months of age, to rickets later in childhood or osteomalacia in adulthood, with a potential for multiorgan involvement. Additionally, this study extensively characterizes infants with ABCC6 variants, allowing for comparison with infants with ENPP1 variants. This enabled us to infer overlapping pathomechanisms for ENPP1 and ABCC6 deficiencies.

Overall survival was 45% and age-dependent, with prenatal death accounting for 24% of total deaths. Risk of mortality was
limited to primarily the first 6 months, with the highest risk just after birth. Of the affected individuals in the full data set, five died after 1 year of age (range, 1.5–12.5 years) due to cardiac (n = 3) and neurological (n = 2) complications. This represents 7% of affected individuals who survived their first year of life (n = 71), which suggests a continued risk of mortality at a young age despite surviving the “critical period” of first 6 months.

At first glance, the minimal data set demonstrated a substantial higher mortality compared to the full data set. However, the difference seems to be driven in part by the higher capture of prenatal deaths (minimal, 19.2%, versus full, 7.9%). When prenatal mortality is removed, the number of deaths is similar between both data sets, which suggests that the full data set is representative of the population.

High prenatal and early life mortality is coupled with extensive arterial calcification due to low PPi levels. It stands to reason that initiation of bisphosphonates, structural analogs of PPi, with high affinity for hydroxyapatite, could improve survival by exogenously compensating for the low PPi levels in infancy. Bisphosphonates consist of a core nonhydrolyzable carbon P-C-P motif that create a more stable (less hydrolyzable) PPi analogue. Etidronate, the first-generation bisphosphonate, binds directly to hydroxyapatite with high affinity, resulting in inhibition of bone mineralization. The second and third generation bisphosphonates (nitrogen-containing) cause osteoclast apoptosis and limit bone resorption. Bisphosphonates have been used to treat GACI with varying degrees of success. A previous study reported 65% survival of GACI patients receiving bisphosphonates compared to 31% of patients who did not (p < 0.026). However, our study found that age of initiation of bisphosphonates varied over the critical period of high mortality, and some patients initiated bisphosphonates after the critical period, when the risk of mortality is much lower. Thus, the start-time matched analysis is an appropriate approach to account for

---

**Fig 3.** (A) Time to bisphosphonate initiation and (B) affected individual-matched KM survival analysis based on bisphosphonate treatment. KM survival estimate for etidronate initiated (C) prenatally or (D) from age of day 7. KM = Kaplan-Meier.
the high rate of death and varied age of bisphosphonate initiation. The results demonstrated no significant benefit in using bisphosphonate. We note a lack of overlap between the confidence intervals around the age of 1 month; however, we caution to not interpret this as validation of bisphosphonate benefit within 1 month. A Kaplan-Meier survival analysis with either etidronate or other bisphosphonates initiated within 6 months of age versus no bisphosphonate treatment found no survival benefit of either cohort if initiated after 7 days of age. Etidronate has been considered the more appropriate option among bisphosphonates, because the goal is to inhibit bone mineralization (as opposed to bone resorption). However, neither etidronate nor other bisphosphonates showed significant differences in the survival curves if initiated after the first week of life. This might suggest that the class of bisphosphonates does not make a difference at an early age. An alternative possibility is that bisphosphonates have no real impact in survival, and that there is a selection bias of which patients (ie, less severe) are treated with bisphosphonates. However, we could not assess for possible variables that account for healthier affected individuals receiving bisphosphonate treatment, or could not account for possible different dose strength and frequency. A prospective study to evaluate bisphosphonate benefit would be required to demonstrate if prenatal or early postnatal initiation provides a benefit. Although our analysis did not show that the use of bisphosphonates in infancy would be beneficial after 7 days of age, it also did not show it would be detrimental to survival. Thus, the decision to use bisphosphonate continues to be at the discretion of the physician and family.

Similar calcification profiles observed in ENPP1 and ABCC6 deficiencies suggest a common pathological mechanism underlying ectopic calcification. There was a very close overlap of frequency and distribution of calcified arteries and aorta between the ENPP1 and ABCC6 cohorts, including the number of arterial beds with calcification found between the two groups. These findings suggest that both ENPP1 and ABCC6 play a role in ectopic calcification, most likely through an overlapping pathway regulating PPi. Patients with ENPP1 variants have very low to barely detectable PPi levels; this has been associated with early onset of arterial calcification. Similarly, adult patients with ABCC6 deficiency and PXE diagnosis exhibited ~50% reduction in plasma PPi levels; consistent findings were reported in Abcc6-mutated mouse models. It is not clear why some patients with ABCC6 variants present with arterial calcification at infancy, whereas others present with PXE as adults. It is possible that the PPi levels are extremely low in this ABCC6-deficient infant population, similar to ENPP1-deficient patients, which might explain the high risk of calcification of arteries and organs similar to infants with ENPP1 deficiency. However, plasma PPi levels in infants with ABCC6 variants have not been reported. No genotype phenotype correlation has been identified for either ENPP1 or ABCC6 deficiencies, suggesting variable expressivity of both ENPP1 and ABCC6 variants. Identical pathogenic variants in ABCC6 or ENPP1 have been shown to cause either PXE or GACI in different patients. Genetic modifications or environmental influences to ENPP1, ABCC6, or other genes could also contribute to the phenotype.

Fig 4. Survival analysis. Kaplan-Meier estimates of survival in ENPP1-deficient and ABCC6-deficient affected individuals aged (A) 0 to 30 years and (B) 0 to 1 year.
TNAP, or CD73 expression or function may contribute to setting the pathogenic levels of PPi in ABCC6-deficient infants.

A trend of higher prevalence of neurological complications was observed in affected individuals with ABCC6 versus ENPP1 variants. Seizures or epilepsy were reported in 13% and 21% of our ENPP1 and ABCC6 cohorts, respectively. Cumulative incidence of epilepsy in the general population is 0.66% at age 10 years, suggesting ENPP1 and ABCC6 variants significantly increase seizure risk. Stroke has been recognized as a complication in patients with ENPP1 deficiency, but this was not based on systematic analyses. The prevalence of stroke in a Dutch adult PXE cohort (n = 178) was higher (8%) versus a general
population matched for age (3%). Our study reports a prevalence of stroke in an ABC6-deficient pediatric cohort. Thus, this study highlights the broad range of neurological complications in both ENPP1 and ABC6 deficiencies, likely consequences of calcification and stenosis in intracranial arteries.

Despite the similar calcification phenotype between ENPP1 and ABC6 deficiencies, there was a disparity in the mortality rate and the presence of rickets in the ENPP1 versus ABC6 cohorts. The risk of mortality was low in ABC6 variants relative to ENPP1 variants. It is interesting to note that cardiovascular complications tend to be the cause of death in individuals with GACI yet affected individuals with ABC6 variants show similar or higher prevalence of cardiovascular complications compared to ENPP1. The factors leading to mortality of individuals with GACI are unknown.

Of the ENPP1-deficient affected individuals that survived the initial critical period, 70% reported signs of rickets. This is in contrast to the three of 18 (17%) with ABC6 variants. Further analysis of the rickets observed in the three ABC6-deficient affected individuals disclosed that it was not accompanied by hypophosphatemia and hyperphosphaturia and was likely a consequence of etidronate administration. It is worth noting that rickets has not been reported in ABC6-deficient adults diagnosed with PXE. This study also identified an ENPP1-deficient population without GACI diagnosis with rickets (ARHR2). Although these cases did not carry a GACI diagnosis, ~70% demonstrated evidence of arterial or organ calcification, symptoms of hearing loss, or cardiovascular complications similar to those seen in survivors of GACI. Together these data show that GACI and rickets (ARHR2) represent a spectrum of ENPP1 deficiency.

It is not clear why there is an overlapping GACI phenotype (arterial calcification with cardiovascular complications) between ENPP1 and ABC6 deficiencies but a difference in the eventual development of rickets with ENPP1 variants. ENPP1 deficiency is associated with elevated FGF23, a bone-derived hormone that regulates renal phosphate reabsorption and vitamin D metabo-lism. Elevated levels of FGF23 result in phosphate wasting and hypophosphatemic rickets. The mechanism underlying elevated FGF23 levels in ENPP1 deficiency has not been elucidated, but it is notable that FGF23 is largely secreted by osteocytes and osteoblasts, where ENPP1 is expressed. Enpp1−/− knockout mice show a 12-fold greater expression of Fgf23 mRNA compared to wild-type littermates, which suggests that ENPP1 function can regulate osteoblastic cellular expression, including elevating FGF23, and thus inducing hypophosphatemic rickets. To our knowledge, elevation of FGF23 has not been reported in ABC6-deficient patients. ABC6 is a transmembrane protein primarily expressed in the liver and kidney, where through an unknown mechanism it exports ATP, among other substrates, into the circulation. Membrane-bound ENPP1 catalyzes the hydrolysis of ATP to AMP, generating PPi, which in turn inhibits mineralization. The functional loss of ABC6 or ENPP1 thereby results in reduced serum PPi and AMP levels, leading to systemic ectopic calcification as seen in mouse models and patients with PXE and/or GACI.

Study limitations are typical of a multicenter retrospective design and include incompleteness/inconsistency in data acquired manually, data limited to available medical records, documentation not systematically recorded for all variables, dates of first observation not reflecting physiologic onset, and lack of standardized assessments. Thus, actual prevalence of clinical manifestations could be higher than what is reported due to incomplete evaluations. Additionally, the number of affected individuals with ABC6 variants was small (n = 19) versus affected individuals with ENPP1 variants. Despite the limitations, this study has demonstrated poor survival in infants during the first 6 months, highlighting the need for new therapies to improve survival.

In summary, this is the largest retrospective study to assess the natural history of GACI or ARHR2, including long-term mortality, and a phenotypic comparison of GACI from ABC6 versus ENPP1 deficiency. Mortality associated with this disorder is highest in the first few months of life, despite bisphosphonate treatment, and is predominant in ENPP1 deficiency. Patients with ENPP1 or ABC6 deficiencies can experience morbidity throughout their life due to multiple organ dysfunctions. The findings of this natural history study provide insight into the complexity of the disease and may help develop more effective management strategies or drive identification of new therapeutics to improve patient prognosis.

Disclosures

CRF reports a collaboration with Inozyme Pharma, Inc. as part of a Cooperative Research and Development Agreement. MEH reports a collaboration with Inozyme Pharma, Inc as part of a Cooperative Research and Development Agreement. MZM received honoraria from Inozyme Pharma, Inc. DS received consulting fees from Inozyme Pharma, Inc. EY is a former employee of Inozyme Pharma, Inc. at the time of the study and owns stock in Inozyme Pharma, Inc. WAG reports a collaboration with Ino-zyme Pharma, Inc. as part of a Cooperative Research and Development Agreement. RIG received nonsalary research support for studies unrelated to this project from the following companies: Ultragenyx Pharmaceutical, QED Therapeutics, Inc, Calcilytic; she is a medical advisor for GACI Global. QL received salary from Inozyme Pharma, Inc. on contract basis. PH is a former employee of Inozyme Pharma, Inc. at the time of the study and owns stock in Inozyme Pharma, Inc. GK is a full-time employee of Inozyme Pharma, Inc. and owns stock in Inozyme Pharma, Inc. FR received nonsalary research support for the conduction of the trial as well as consultancy fees from Inozyme Pharma, Inc. KK, UB, YN, and GB have no conflict of interest. All authors have potential conflicts of interests denoted in this section. The authors who have no conflicts of interest to declare are listed as such. Please confirm if more information is required.

Acknowledgments

This work was supported, in part, by the Intramural Research Program of the National Human Genome Research Institute. WAG is supported by the Intramural Research Program of the National Institute of Dental and Craniofacial Research. YN and FR are supported by the COST network CA16115 – A European Network for Connective Tissue Calculifying Diseases. The study was funded by Inozyme Pharma, Inc. Writing and editorial support was provided by PRECISIONsclentia, Inc, in accordance with Good Publication Practice (GPP3) guidelines, and was funded by Inozyme Pharma, Inc. The authors were responsible for all content and editorial decisions and received no honoraria related to the development of this manuscript. We thank the patients, their families, all other investigators, and all investigational site members involved in this study. We also thank the following individuals who contributed to this study: Angel Alonso Sanchez, Nathaly Alos, David Amor, Paul Arundel, Svitlana Bachurska, Veronique Baudouin, Soreka Bollepilli, Horst Buxmann, Moira Cheung, Anne Marie Coady, Aytul Corbacioglu, Carla Corti, Asmaa Dibi, Klaus Dieterich, Asli Ece Solmaz, Renata Gaillyova, Sam Garber, Mamatha
Gowda, Elif Yilmaz Gulec, Lior Haftel, Tongyan Han, Hanna Huo-pio, Ivathyth Kalal Goud, André Kroon, Melissa Lees, Anja Lehner, Alice Maltret, Sahar Mansour, Jelena Martinovic, Craig Munns, Talat Mushthaq, Sheela Namphothingh, Munier Nour, Bruce Pawel, Thomas Perouse De Montclos, Renuka Ramakrishnan, Marianne Rohrbach, Carola Saloranta, Ulla Sanklami, Lucia Santoro, SENTHIL Senniapan, Mercedes Serrano, Nick Shaw, Ingrid Sinner-brink, Christine Burt Solorzano, Robert Stavis, Elisabeth Steichen, Margot Van Allen, A.T.H. van Dijk, Emma Wakeling, Michael Whyte, David Chitayat, Stefano Sartori, Jean-Jacques Roux, Abbas Moosa Al Omran, Osvaldo Artigalas, Eva-Lena Stattin, Ozge Pamukcu, Raja Paddidela, G. Karthikeyan, Yvonne Hendricks, Hephzibah Rani, James Tibballs, Eadaoin Hayes, Sisi Wang, and Kerstin Müller. Frank Rutsch and Gus Khursigara had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Authors’ roles: All authors made substantial contributions to the study; CRF, GK, and FR drafted the manuscript and all authors reviewed and revised it critically; all authors approved the final version of the submitted manuscript.

Data Availability Statement

The data that support the findings of this study are available from the corresponding authors upon reasonable request.

References

1. MedlinePlus. Generalized arterial calcification of infancy. Page last updated: August 18, 2020. Page last reviewed: January 1, 2015. Available from: https://ghr.nlm.nih.gov/condition/generalized-arterial-calcification-of-infancy#statistics. Accessed August 9, 2021.

2. Chong CR, Hutchins GM. Idiopathic infantile arterial calcification: the spectrum of clinical presentations. Pediatr Dev Pathol. 2008;11(5): 405-415.

3. Ziegler SG, Gahl WA, Ferreira CR. Generalized arterial calcification of infancy. In Adam MP, Arding HE, Pagon RA, et al., eds. GeneReviews® [Internet]. Seattle, WA: University of Washington; 1993 pp 2020-2014. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK253403/. Accessed August 9, 2021.

4. Rutsch F, Büyer P, Nitschke Y, et al. Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. Circ Cardiovasc Genet. 2008;1(2):133-140.

5. Bellah RD, Zawodniak L, Librizzi RJ, Harris MC. Idiopathic arterial calcification of infancy: prenatal and postnatal effects of therapy in an infant. J Pediatr. 1992;121(6):930-933.

6. Meradji M, de Villeneuve VH, Huber J, de Bruijn WC, Pearse RG. Idiopathic arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6. Am J Hum Genet. 2012;90(1):25-39.

7. Nitschke Y, Bajaut G, Botschen U, et al. Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABC6. Am J Hum Genet. 2012;90(1):25-39.

8. Goding JW, Grobben B, Slegers H. Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family. Biochim Biophys Acta. 2003;1638(1):1-19.

9. Albayrak G, Siljestre E, Ergur B, et al. Inhibitory effect of adenosine on intimal hyperplasia and proliferation of smooth muscle cells in a carotid arterial anastomosis animal model. Vascular. 2015;23(2):124-131.

10. Jansen RS, Duijst S, Mahakama S, et al. ABC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report. Arterioscler Thromb Vasc Biol. 2014;34(9):1985-1989.

11. Nitschke Y, Yan Y, Buers I, Kintziger K, Askew K, Rutsch F. ENPP1-Fc prevents neo-intima formation in generalized arterial calcification of infancy through the generation of AMP. Exp Mol Med. 2018;50(10):1-12.

12. Jansen RS, Küçükosmanoglou A, de Haas M, et al. ABC6C prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release. Proc Natl Acad Sci U S A. 2013;110(50):20206-20211.

13. Kauffenstein G, Yegutkin GG, Khiati S, et al. Alteration of extracellular nucleotide metabolism in pseudoxanthoma elasticum. J Invest Dermatol. 2018;138(8):1862-1870.

14. Boyce AM, Gafni RI, Ferreira CR. Generalized arterial calcification of infancy: new insights, controversies, and approach to management. Curr Osteoporos Rep. 2020;18(3):232-241.

15. Ferreira CR, Hackbarth ME, Ziegler SG, et al. Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI). Genet Med. 2021;23(2):396-407.

16. Levy-Litan V, Hershkovitz E, Avizov L, et al. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet. 2010;86(2):273-278.

17. Lorenz-Depiereux B, Schnabel D, Tissano D, Häusler G, Strom TM. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet. 2010;86(2):267-272.

18. Li Q, Brodsky JL, Conlin LK, et al. Mutations in the ABC6C gene as a cause of generalized arterial calcification of infancy: genotypic overlap with pseudoxanthoma elasticum. J Invest Dermatol. 2014;134(3):658-665.

19. Uttjo J, Bercovitch L, Terry SF, Terry PF. Pseudoxanthoma elasticum: progress in diagnostics and research towards treatment: summary of the 2010 PXE International Research Meeting. Am J Med Genet A. 2011;155a(7):1517-1526.

20. Naouri M, Boisseau C, Bonipel C, et al. Manifestations of pseudoxanthoma elasticum in childhood. Br J Dermatol. 2009;161(3):635-639.

21. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032-1045.

22. Nitschke Y, Rutsch F. Genetics in arterial calcification: lessons learned from rare diseases. Trends Cardiovasc Med. 2012;22(6):145-149.

23. Aaberg KM, Gunness N, Bakken U, et al. Incidence and prevalence of childhood epilepsy: a nationwide cohort study. Pediatrics. 2017;139(5):e20163908.

24. Kauw F, Kranenburg G, Kappelle LJ, et al. Cerebral disease in a nationwide Dutch pseudoxanthoma elasticum cohort with a systematic review of the literature. J Neurol Sci. 2017;373:167-172.

25. Oheim R, Zimmerman K, Maudling ND, et al. Human heterozygous ENPP1 deficiency is associated with early onset osteoporosis, a phenotype recapitulated in a mouse model of Enpp1 deficiency. J Bone Miner Res. 2020;35(3):528-539.

26. Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev. 2012;92(1):131-155.

27. Maudling ND, Kavanagh D, Zimmerman K, et al. Genetic pathways disrupted by ENPP1 deficiency provide insight into mechanisms of osteoporosis, osteomalacia, and paradoxical mineralization. Bone. 2021;142:115656.

28. Beck-Nielsen SS, Mughal Z, Haffner D, et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis. 2019;14(1):58.

29. Laurent MR, De Schepper J, Trouet D, et al. Consensus recommendations for the diagnosis and management of X-linked hypophosphatemia in Belgium. Front Endocrinol. 2021;12:641543.

30. Mackenzie NC, Zhu D, Milne EM, et al. Altered bone development and an increase in FGF-23 expression in Enpp1(−/−) mice. PLoS One. 2012;7(2):e32177.

31. Zhou X, Cui Y, Zhou X, Han J. Phosphate/pyrophosphate and MV-related proteins in mineralisation: discoveries from mouse models. Int J Biol Sci. 2012;8(6):778-790.

32. Shimada BK, Pomozi V, Zoll J, Kuo S, Martin L, Le Saux O, ABC6C, pyrophosphate and ectopic calcification: therapeutic solutions. Int J Mol Sci. 2021;22(9):4555.